Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

  • STATUS
    Not Recruiting
  • participants needed
    30
  • sponsor
    Cerecor Inc
Updated on 6 July 2022
platelet count
cell transplantation
neutrophil count
refractory multiple myeloma

Summary

This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma.

The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.

Details
Condition Multiple Myeloma
Treatment AEVI-007
Clinical Study IdentifierNCT04671251
SponsorCerecor Inc
Last Modified on6 July 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note